Table 1 Baseline demographic, anthropometric and biochemical characteristics

From: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

Clinical Variable

AZD4017 (n = 15)

Placebo (n = 15)

Age, yr

36.5 (11.0)

39.0 (12.7)

Weight, kg

79.9 (8.7)

83.1 (8.5)

BMI, kg/m2

24.5 (2.5)

25.8 (2.0)

SBP, mm Hg

135.7 (10.6)

138.3 (14.4)

DBP, mm Hg

78.5 (9.8)

79.6 (11.4)

HbA1c, mmol/mol

34.0 (32.0–37.0)

35.0 (33.0–36.0)

Fasting glucose, mmol/L

4.6 (4.3–5.5)

4.9 (4.4–5.1)

Fasting insulin, mU/L

3.13 (1.79–6.60)

2.84 (1.36–5.17)

HDL cholesterol, mmol/L

1.3 (0.3)

1.3 (0.3)

Total cholesterol, mmol/L

5.0 (1.2)

4.6 (0.9)

AST, IU/L

21.3 (4.5)

21.6 (6.7)

Bilirubin, mmol/L

15.3 (5.3)

15.0 (5.6)

ALT, IU/L

21.0 (5.2)

18.8 (5.5)

ALP, IU/L

52.9 (8.9)

57.3 (11.6)

Albumin, g/L

39.5 (2.6)

38.5 (2.3)

TSH, mIU/L

1.4 (1.3–1.8)

1.5 (1.0–1.9)

Androstenedione, nmol/L

8.4 (5.9–9.4)

6.4 (5.3–8.1)

DHEAS, μmol/L

11.2 (5.5–15.1)

6.7 (4.2–12.2)

SHBG, nmol/L

33.4 (16.5)

35.6 (15.9)

Testosterone, nmol/L

18.4 (15.0–23.1)

18.7 (13.6–22.0)

ACTH, ng/L

21.9 (18.1–52.9)

30.5 (16.9–54.6)

Cortisol, nmol/L

372.7 (117.2)

385.7 (77.1)

  1. Data are expressed as mean (SD) or median (IQR).
  2. ACTH adrenocorticotropic hormone, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, DBP diastolic blood pressure, DHEAS dehydroepiandrosterone sulphate, DHT dihydrotestosterone, HbA1c glycated haemoglobin, HDL high-density lipoprotein, SBP systolic blood pressure, SHBG sex-hormone binding globulin, TSH thyroid stimulating hormone.
Back to article page